Henderson L W
Baxter Healthcare Corporation, McGaw Park, IL 60085, USA.
Adv Ren Replace Ther. 1998 Oct;5(4):333-40. doi: 10.1016/s1073-4449(98)70026-3.
The view of dialysis in the next 5 years will, by requirement, deal with ideas presently in the laboratories of industry and academics. The healthcare environment is heavily cost constrained and will likely only yield to more expensive therapies if one measures them in pharmacoeconomic terms and shows that they reduce the life costs for a patient with end-stage renal disease. The technologies of hemodialysis and peritoneal dialysis appear to be moving toward one another in terms of generating sterile pyrogen-free dialysis fluid online and moving toward customization of therapy for the individual patient. Sensors will provide closed loop feedback to modulate therapy prescription intradialytically for hemodialysis and on an exchange-to-exchange basis for continuous ambulatory peritoneal dialysis. Hemodialysis will, in part, move back into the home as new, smart, and smaller equipment prospectively designed for that purpose becomes available. Renewed interest in vascular access will provide alternatives to the present shunt and fistula. The recognition of middle molecule toxicity may require selective removal of identified toxins by immunoadsorption. Patient, rather than physician, quality of life will largely dictate the acceptance of technical innovation over the next 5 years.
未来5年的透析展望将根据要求,涉及目前工业界和学术界实验室中的想法。医疗保健环境受到严重的成本限制,并且如果从药物经济学角度衡量并表明它们能降低终末期肾病患者的生活成本,才可能采用更昂贵的治疗方法。血液透析和腹膜透析技术在在线生成无菌无热原透析液以及朝着为个体患者定制治疗方案方面似乎正在相互靠拢。传感器将提供闭环反馈,以便在血液透析期间对治疗处方进行透析内调节,并在持续非卧床腹膜透析中逐次交换进行调节。随着前瞻性设计用于家庭的新型、智能且更小的设备问世,血液透析将部分回归家庭。对血管通路的重新关注将为目前的分流术和造瘘术提供替代方案。对中分子毒性的认识可能需要通过免疫吸附选择性清除已确定的毒素。在未来5年,患者而非医生的生活质量将在很大程度上决定对技术创新的接受程度。